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Pericytes play a central role in regulating the structure and function of capillaries in the
brain. However, molecular mechanisms that drive pericyte proliferation and differentiation
are unclear. In our study, we immunostained NACHT, LRR and PYD domains-
containing protein 3 (NLRP3)-deficient and wild-type littermate mice and observed that
NLRP3 deficiency reduced platelet-derived growth factor receptor β (PDGFRβ)-positive
pericytes and collagen type IV immunoreactive vasculature in the brain. In Western
blot analysis, PDGFRβ and CD13 proteins in isolated cerebral microvessels from the
NLRP3-deficient mouse brain were decreased. We further treated cultured pericytes
with NLRP3 inhibitor, MCC950, and demonstrated that NLRP3 inhibition attenuated
cell proliferation but did not induce apoptosis. NLRP3 inhibition also decreased protein
levels of PDGFRβ and CD13 in cultured pericytes. On the contrary, treatments with
IL-1β, the major product of NLRP3-contained inflammasome, increased protein levels
of PDGFRβ, and CD13 in cultured cells. The alteration of PDGFRβ and CD13 protein
levels were correlated with the phosphorylation of AKT. Inhibition of AKT reduced both
protein markers and abolished the effect of IL-1β activation in cultured pericytes. Thus,
NLRP3 activation might be essential to maintain pericytes in the healthy brain through
phosphorylating AKT. The potential adverse effects on the cerebral vascular pericytes
should be considered in clinical therapies with NLRP3 inhibitors.
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INTRODUCTION
Brain pericytes wrapping around endothelial cells regulate various functions in the brain,
which include blood-brain barrier (BBB) permeability, angiogenesis, and capillary hemodynamic
responses (Sweeney et al., 2016). Pericytes express platelet-derived growth factor receptor
β (PDGFRβ) and CD13. The binding of PDGFRβ with endothelial cells-released platelet-
derived growth factor (PDGF)-B is essential for pericyte proliferation and integration into
the blood vessel (Lindahl et al., 1997). CD13 promotes angiogenesis in hypoxic tissues, and
response to stimulation of angiogenic growth factors, such as vascular endothelial growth
Abbreviations: Aβ, amyloid β peptide; AD, Alzheimer’s disease; APP, Alzheimer’s precursor protein; BBB, blood-brain
barrier; BDNF, brain-delivered neurotrophic factor; HBPC, human primary brain vascular pericytes; HBSS, Hanks’
balanced salt solution; IL-1β, interleukin-1β; LPS, lipopolysaccharide; MyD88, myeloid differentiation primary response
88; NLRP, NACHT, LRR and PYD domains-containing protein; PCNA, proliferating cell nuclear antigen; PDGFRβ,
platelet-derived growth factor receptor β; TLR, Toll-like receptor; TNF-α, tumor necrosis factor α.
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factor, basic fibroblast growth factor, and transforming growth
factor (Rangel et al., 2007). Deficiency of PDGFRβ decreases
pericyte number, accumulates blood-derived fibrin/fibrinogen,
reduces vasculature, and attenuates blood flow in the
mouse brain, which finally leads to the white matter lesions
characterized by loss of oligodendrocytes, demyelination, and
axonal degeneration (Montagne et al., 2018). Growing evidence
suggests that pericyte impairment mediates vascular dysfunction
and contributes to the pathogenesis of Alzheimer’s disease (AD;
Love and Miners, 2016). In the AD human brain, pericytes are
lost in association with increased BBB permeability at a very early
disease stage (Sengillo et al., 2013; Nation et al., 2019). In AD
mouse models that overexpress Alzheimer’s precursor protein
(APP) in neurons, the deletion of pericytes increases deposition
of amyloid β peptide (Aβ) in both brain parenchyma and blood
vessels, which potentially exaggerates cognitive deficits (Sagare
et al., 2013). However, molecular mechanisms that regulate
pericyte survival and activation in the brain are largely unknown.
Pericytes express pattern recognition receptors, such as
Toll-like receptor 2 and 4 (TLR-2 and -4) and NACHT, LRR
and PYD domains-containing protein 1 and 3 (NLRP-1 and -3;
Guijarro-Muñoz et al., 2014; Leaf et al., 2017; Nyúl-Tóth et al.,
2017). Cultured brain pericytes release cytokines and chemokines
after being challenged with lipopolysaccharide (LPS), tumor
necrosis factor (TNF)-α or E. coli infection (Kovac et al.,
2011; Guijarro-Muñoz et al., 2014; Nyúl-Tóth et al., 2017).
Cultured pericytes secret active interleukin (IL)-1β when they
are intracellularly stimulated with LPS, although how NLRP3-
contained inflammasome is activated remains unclear (Nyúl-
Tóth et al., 2017). It is interesting to ask whether innate
immune signaling regulates cell fate and functions of pericytes in
the brain.
In AD research, NLRP3-contained inflammasome attracted
great attention, as it is activated in AD brain and potentially
mediates microglial inflammatory responses, exaggerates Aβ and
Tau protein aggregation in APP or Tau-transgenic mice (Heneka
et al., 2013; Venegas et al., 2017; Ising et al., 2019; Stancu et al.,
2019). NLRP3 is considered as a promising therapeutic target
for AD patients (Dempsey et al., 2017). However, the effects of
NLRP3 activation on pericytes and vascular dysfunction were not
addressed. The animal models used in published studies have
also limited AD-associated vascular pathology. Thus, whether
NLRP3 inhibition protects or damages microvascular circulation
in the AD brain remains unclear. Moreover, AD pathology
is mainly localized in temporal and parietal lobes, instead of
covering the whole brain. Between AD lesion sites as shown
with Aβ deposits, neurofibrillary tangles, and gliosis, the brain
tissues are relatively or absolutely healthy (Deture and Dickson,
2019). It is, therefore, necessary to understand the physiological
function of NLRP3 in brain pericytes, which is helpful to predict
potential off-target effects of NLRP3 inhibitors in the future
anti-AD therapies.
In this study, we used NLRP3-knockout mice and treated
cultured pericytes with NLRP3 inhibitor, MCC950, or IL-
1β, a major product of NLRP3-contained inflammasome. We
observed that NLRP3 might be essential for the maintenance of
healthy pericytes in the brain. We further observed that AKT
(also known as protein kinase B) might mediate the physiological
function of NLRP3 in pericytes.
MATERIALS AND METHODS
Mice
NLRP3-encoding gene knockout (NLRP3−/−) mice were kindly
provided by N. Fasel (University of Lausanne, Lausanne,
Switzerland; Martinon et al., 2006). Mice with the knockout
of gene encoding myeloid differentiation primary response 88
(MyD88−/−) were originally provided by S. Akira and K. Takeda
(Osaka University, Osaka, Japan; Adachi et al., 1998). Breeding
between heterozygous mutants (+/−) on a C57BL/6 background
was used to maintain mouse colonies. Mice were compared
only between littermates. Animal experiments were performed
following all relevant national rules and were authorized by the
local research ethics committee.
Tissue Collection and Isolation of Blood
Vessels
Animals were euthanized by inhalation of isoflurane and
perfused with ice-cold phosphate-buffered saline. The brain was
removed and divided. The left hemisphere was immediately
fixed in 4% paraformaldehyde (Sigma-Aldrich Chemie GmbH,
Taufkirchen, Germany) for immunohistochemistry. The cortex
and hippocampus from the right hemisphere were carefully
dissected and brain vessel fragments were isolated according to
the published protocol (Boulay et al., 2015). Briefly, brain tissues
were homogenized in HEPES-contained Hanks’ balanced salt
solution (HBSS) and centrifuged at 4,400 g in HEPES-HBSS
buffer supplemented with dextran from Leuconostoc spp.
(molecular weight ∼70,000; Sigma-Aldrich) to delete myelin.
The vessel pellet was re-suspended in HEPES-HBSS buffer
supplemented with 1% bovine serum albumin (Sigma-Aldrich)
and filtered with 20 µm-mesh. The blood vessel fragments were
collected on the top of the filter for biochemical analysis and
stored at −80◦C for biochemical analysis.
Histological Analysis
To analyze pericytes in capillaries, serial 30-µm-thick sagittal
sections were cut from the dehydrated and cryoembedded left
brain hemisphere with a Leica cryostat (Leica Mikrosysteme
Vertrieb, Wetzlar, Germany). Three sections per mouse with
300 µm of an interval between neighboring layers were
used. Antigen retrieval was performed by heating sections
in 10 µM citrate buffer (pH = 6). After blocking with
5% goat serum in PBS/0.3% Triton X-100, brain sections
were incubated with rabbit anti-PDGFRβ monoclonal antibody
(clone: 28E1; Cell Signaling Technology Europe, Frankfurt am
Main, Germany) at 4◦C overnight and then Alexa488-conjugated
goat anti-rabbit IgG (Thermo Fisher Scientific, Darmstadt,
Germany) at room temperature for 1 h. Thereafter, brain sections
were further stained with biotin-labeled Griffonia simplicifolia
Lectin I isolectin B4 (Catalog: B-1205; Vector Laboratories,
Burlingame, CA, USA) and Cy3-conjugated streptavidin (Roche
Applied Science, Mannheim, Germany). The whole cortex
was imaged under a Zeiss AxioImager.Z2 microscope (Carl
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Zeiss Microscopy GmbH, Göttingen, Germany) equipped with
a Stereo Investigator system (MBF Bioscience, Williston,
VT, USA). Ten regions per section were randomly chosen
under a 40× objective. Blood vessels with <6 µm of
diameter were examined. Fluorescence-labeled areas were
measured with ImageJ software1. The coverage of pericytes
was calculated as a ratio of PDGFRβ/isolectin B4-positive
staining area.
To detect the expression of NLRP3 in pericytes, brain sections
were incubated at 4◦C overnight with mouse anti-NLRP3
monoclonal antibody (clone: Cryo-2; AdipoGen Life Sciences,
San Diego, CA, USA), which was followed by incubation with
Cy3-conjugated goat anti-mouse IgG (Jackson ImmunoResearch
Europe Ltd., Cambridgeshire, UK) at room temperature for
1 h. Thereafter, brain sections were further stained with rabbit
anti-PDGFRβ monoclonal antibody and Alexa488-conjugated
goat anti-rabbit IgG as described above. Stack images were
acquired with a Zeiss AxioImager.Z2 microscope under a 63×
oil objective with an interval of 0.2 µm between neighboring
layers, processed with deconvolution and finally Z-projected with
maximum intensity.
For analysis of the impairment of BBB in NLRP3-deficient
mice, brain sections from NLRP3 - knockout and wild-type mice
were stained with Alexa488-conjugated goat anti-mouse IgG
(Thermo Fisher Scientific) after blocking with goat serum as we
did in a previous study (Hao et al., 2011), and co-stained with
biotinylated isolectin B4 and Cy3-conjugated streptavidin.
To quantify vasculature in the brain, our established protocol
was used (Decker et al., 2018). The left hemisphere was
embedded in paraffin and 40-µm-thick sagittal sections were
serially cut. Four serial sections per mouse with 400 µm
of distance in between were deparaffinized, heated at 80◦C
in citrate buffer (10 mM, pH = 6) for 1 h, and digested
with Digest-All 3 (Pepsin; Thermo Fisher Scientific) for
20 min. Thereafter, brain sections were stained with rabbit
anti-collagen IV polyclonal antibody (Catalog: #ab6586; Abcam,
Cambridge, UK) and Alexa488-conjugated goat anti-rabbit IgG
(Thermo Fisher Scientific). After being mounted, the whole
brain including the hippocampus and cortex was imaged with
Microlucida (MBF Bioscience). The length and branching points
of collagen type IV staining-positive blood vessels were analyzed
with free software, AngioTool2 (Zudaire et al., 2011). The
parameters of analysis for all compared samples were kept
constant. The length and branching points were adjusted with an
area of interest.
Western Blot Analysis
Isolated blood vessels were lysed in RIPA buffer [50 mM Tris (pH
8.0), 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1%
NP-40, and 5 mM EDTA] supplemented with protease inhibitor
cocktail (Roche Applied Science) on ice. The tissue lysate was
sonicated before being loaded onto 10% SDS-PAGE. For Western
blot detection, rabbit monoclonal antibodies against PDGFRβ
and CD13/APN (clone: 28E1 and D6V1W, respectively; Cell
1https://imagej.nih.gov/ij/
2https://ccrod.cancer.gov/confluence/display/ROB2/
Signaling Technology Europe) were used. In the same sample,
β-actin was detected as a loading control using a rabbit
monoclonal antibody (clone: 13E5; Cell Signaling Technology
Europe). Western blots were visualized via the ECL method
(PerkinElmer LAS GmbH, Rodgau, Germany). Densitometric
analysis of band densities was performed with ImageJ software.
For each sample, the protein level was calculated as a ratio of
target protein/β-actin.
Culture of Pericytes
Human primary brain vascular pericytes (HBPC) were
immortalized by infecting cells with tsSV40T lentiviral particles
(Umehara et al., 2018). The selected immortalized HBPC clone
37 (hereafter referred to as HBPC/ci37) was used for our study.
HBPC/ci37 cells were cultured at 33◦C with 5% CO2/95%
air in pericyte medium (Catalog: #1201; Sciencell Research
Laboratories, Carlsbad, CA, USA) containing 2% (v/v) fetal
bovine serum, 1% (w/v) pericyte growth factors, and penicillin-
streptomycin. Culture flasks and plates were treated with
Collagen Coating Solution (Catalog: #125-50; Sigma-Aldrich).
HBPC/ci37 cells were used at 40–60 passages in this study.
Analysis of Pericyte Proliferation and
Apoptosis
Pericytes were seeded at 1.0 × 104 cells on 96-well plate/100 µl
(day 0), and cultured in pericyte medium containing
NLRP3 inhibitor, MCC950 (Catalog: #PZ0280; Sigma-Aldrich),
at 0, 25, 50 and 100 nM, or containing recombinant human
IL-1β (Catalog: #201-LB; R&D Systems, Wiesbaden, Germany)
at 0, 5, 10 and 50 ng/ml. The cell survival was detected with
MTT-based Cell Proliferation Kit I (Catalog: #11465007001;
Sigma-Aldrich) on days 1, 2, 3, 4, 5, 6 and 7. In MTT assay,
yellow and water-soluble 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) enters viable cells and
passes into the mitochondria where it is reduced by succinate
dehydrogenase to an insoluble, dark purple formazan product.
The measured absorbance as shown with optical density (OD) at
590 nm is proportional to the number of viable cells.
To further detect cell death and proliferation of pericytes, cells
were cultured in 12-well plate at 5.0 × 105 cells/well, and treated
with MCC950 as described in MTT assay. After 24 h, pericytes
were collected and lysed in RIPA buffer. Quantitative Western
blot was used with rabbit monoclonal antibody against cleaved
caspase-3 (clone: 5A1E; Cell Signaling Technology Europe),
mouse monoclonal antibody against proliferating cell nuclear
antigen (PCNA; clone: PC10; Cell Signaling Technology Europe)
and rabbit monoclonal antibody against Ki-67 (clone: SP6;
Abcam). α-tubulin and β-actin were detected as internal control
with mouse monoclonal antibody (clone: DM1A; Abcam)
and rabbit monoclonal antibody (clone: 13E5; Cell Signaling
Technology Europe), respectively.
In this experiment, we also detected NLRP3 and cleaved
caspase-1 in the cell lysate from pericytes with and without
treatment of MCC950, with rabbit monoclonal antibodies against
NLRP3 and cleaved caspase-1 (Asp297; clone D4D8T and
D57A2; Cell Signaling Technology Europe), respectively.
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Treatments of Pericytes for Detection of
PDGFRβ and CD13 and Phosphorylated
Kinases
Pericytes were cultured in a 12-well plate at 5.0 × 105 cells/well.
Before experiments, we replaced the culture medium with
serum-free pericyte medium and cultured cells at 37◦C for
3 days to facilitate cell differentiation (Umehara et al., 2018).
Thereafter, pericytes were treated for 24 h with MCC950, at
0, 25, 50 and 100 nM, recombinant human IL-1β (Catalog:
#201-LB; R&D Systems) at 0, 5, 10 and 50 ng/ml, or AKT
Inhibitor VIII (Catalog: #124018; Sigma-Aldrich) at 0, 0.5, 1 and
5 µM. To investigate whether AKT mediates the effect of IL-1β,
pericytes were pre-treated with 1 µM AKT inhibitor VIII for
1 h and then incubated with IL-1β at various concentrations
in the presence of AKT inhibitor for 24 h. The cell lysate
was prepared in RIPA buffer supplemented with protease
inhibitor cocktail (Roche Applied Science) and phosphatase
inhibitors (50 nM okadaic acid, 5 mM sodium pyrophosphate,
and 50 mM NaF; Sigma-Aldrich). For quantitative Western
blot, the following antibodies were used: rabbit monoclonal
antibodies against PDGFRβ, CD13/APN, phosphorylated
AKT (Ser473), phosphorylated ERK1/2 (Thr202/Tyr204),
phosphorylated NFκB p65 (S536), NFκB p65, β-actin, GAPDH
(clone: 28E1, D6V1W, D9E, D13.14.4E, 93H1, D14E12, 13E5,
and 14C10, respectively; Cell Signaling Technology Europe),
rabbit polyclonal antibodies against AKT and phosphorylated
GSK-3β (Ser9; Catalog: #9272 and Catalog: #9336, respectively;
Cell Signaling Technology Europe) and mouse monoclonal
antibodies against ERK1/2 and GSK-3β (clone: L34F12 and
3D10, respectively; Cell Signaling Technology Europe) and
α-tubulin (clone: DM1A; Abcam).
Statistics
Data were presented as mean ± SEM for mice and mean ± SD for
cells. For multiple comparisons, one-way or two-way ANOVA
followed by Bonferroni or Tukey post hoc test. Two independent-
samples Students t-test was used to compare means for two
groups of cases. All statistical analyses were performed with
GraphPad Prism 5 version 5.01 for Windows (GraphPad
Software, San Diego, CA, USA). Statistical significance was set
at p < 0.05.
RESULTS
NLRP3 Deficiency Reduces Pericyte Cell
Coverage and Decreases Protein Levels of
PDGFRβ and CD13 in the Brain
To explore the effects of NLRP3 on the maintenance of
pericytes in the brain, we first detected the expression of
NLRP3 in pericytes. In brain sections, we observed widely
distributed NLRP3-immune reactive cell bodies and processes,
part of which were co-stained by PDGFRβ-specific antibodies
(Figure 1A), which suggests that pericytes express NLRP3.
Then, we estimated the coverage of PDGFRβ-positive cells in
brains from 9-month-old NLRP3-knockout (NLRP3−/− and
NLRP3+/−) and wild-type (NLRP3+/+) littermate mice. As shown
in Figures 1B,C, deficiency of NLRP3 significantly decreased
the coverage of PDGFRβ-immune reactive cells in microvessels
with < 6 µm of diameter in a gene dose-dependent manner
as compared with that in NLRP3-wildtype mice (one-way
ANOVA, p < 0.05; n = 4 per group). We continued to
isolate blood vessels from brains of 9-month-old NLRP3−/−,
NLRP3+/− and NLRP3+/+ littermate mice for the detection of
pericyte protein markers, PDGFRβ, and CD13. We observed
that the deletion of NLRP3 significantly reduced PDGFRβ
and CD13 proteins in the cerebral blood vessels also in a
gene dose-dependent manner (Figures 1D,E; one-way ANOVA,
p < 0.05; n ≥ 7 per group). Unfortunately, we failed to detect
cleaved caspase-3 and PCNA in the tissue lysate of blood vessels
(data not shown), which are markers for cell apoptosis and cell
proliferation, respectively.
In further experiments, we asked whether innate immune
signaling serves a common effect on pericyte survival in
the brain. We detected PDGFRβ and CD13 proteins in
cerebral blood vessels isolated from 6-month-old MyD88−/−,
MyD88+/− and MyD88+/+ littermate mice. MyD88 is a
common adaptor down-stream to most TLRs and mediates the
inflammatory activation of IL-1β (O’Neill and Bowie, 2007).
We observed that protein levels of CD13 and PDGFRβ were
significantly lower in MyD88-deficient mice than in MyD88-
wildtype controls (Figures 1F,G; one-way ANOVA, p < 0.05;
n ≥ 6 per group).
NLRP3 Deficiency Reduces Vasculature in
the Brain
Pericytes are essential for the development of cerebral
circulation. Dysfunction of pericytes reduces vasculature
and increases the permeability of BBB (Sweeney et al., 2016;
Montagne et al., 2018). We asked whether NLRP3 deficiency
affects the structure of cerebral blood vessels. We observed that,
in 9-month-old mouse brains, deficiency of NLRP3 significantly
reduced the total length and branching points of collagen
type IV-positive blood vessels (Figures 2A–C; one-way
ANOVA, p < 0.05; n ≥ 6 per group). The reduction of
brain vasculature was dependent on the copies of the NLRP3-
encoding gene. However, we did not detect IgG leakage into
the brain parenchyma, which suggested that the intactness of
BBB in NLRP3-deficient mice was not severely damaged (see
Figure 2D).
NLRP3 Inhibition Attenuates Cell
Proliferation in Cultured Pericytes
After we observed that NLRP3 deficiency decreased
the number of pericytes in the brain, we continued to
investigate whether NLRP3 directly regulates the proliferation
and death of pericytes. We detected NLRP3 proteins in
our cultured pericytes with different passaging numbers
(Figure 3A). We also detected cleaved caspase-1 in pericytes,
with the remarked reduction of proteins after cells were
treated with NLRP3 inhibitor, MCC950 (Figure 3B).
Thus, the NLRP3-caspase-1 signaling pathway is active in
pericytes and potentially regulates the cellular function.
Activated caspase-1 cleaves pro-IL-1β into active IL-1β
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FIGURE 1 | NLRP3 deficiency reduces pericyte cell coverage and decreases protein levels of PDGFRβ and CD13 in the brain. (A) Nine-month-old mouse brains
were co-stained for NLRP3 and PDGFRβ. PDGFRβ-immune reactive cell bodies (in green; marked with arrows) were stained by NLRP3-specific antibodies (in red).
(B) Brain tissues from 9-month-old NLRP3-knockout (−/− and +/−) and wild-type (+/+) littermate mice were then co-stained for PDGFRβ (with anti-PDGFRβ
antibodies, in green) and endothelial cells (with isolectin B4, in red). (C) The coverage of PDGFRβ-positive pericytes was calculated as a ratio of PDGFRβ/isolectin
B4-positive area. One-way ANOVA followed by Tukey post hoc test, n = 4 per group. (D–G) Nine-month-old NLRP3, and 6-month-old MyD88 littermate mice with
homozygous (−/−) and heterozygous (+/−) knockout, and wild-type (+/+) of nlrp3 and myd88 genes, respectively, were analyzed for protein levels of PDGFRβ and
CD13 in isolated cerebral blood vessels. One-way ANOVA followed by Bonferroni post hoc test, n = 10, 10 and 8 for NLRP3 (+/+, +/− and −/−) mice in PDGFRβ
detection and n = 9, 9 and 7 for NLRP3 (+/+, +/− and −/−) mice in CD13 detection; n = 8, 10 and 6 for MyD88 (+/+, +/− and −/−) mice in the detection of both
PDGFRβ and CD13. *p < 0.05 and **p < 0.01.
(Gross et al., 2011). However, we were not able to show
that NLRP3 inhibition reduced IL-1β secretion as the IL-1β
release from non-activated pericytes was undetectable (data are
not shown).
Then, we investigated whether NLRP3 regulates pericyte
proliferation. After treating cultured pericytes with MCC950 at
different concentrations, we observed that NLRP3 inhibition
significantly reduced the conversion of MTT into its colorful
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FIGURE 2 | NLRP3 deficiency reduces vasculature in the brain. (A) The
brains of 9-month-old littermate mice with homozygous (−/−), heterozygous
(+/−), and wild-type (+/+) of nlrp3 gene were stained for collagen type IV (Col
IV). The blood vessels in the hippocampus were thresholded and
skeletonized. The skeleton representation of vasculature is shown in red and
branching points of blood vessels are in blue. (B,C) The total length and
branching points of blood vessels were calculated and adjusted by area of
analysis. One-way ANOVA followed by Bonferroni post hoc test, n = 8, 8, and
6 for NLRP3 (+/+, +/− and −/−) mice, respectively. **p < 0.01.
(D) Nine-month-old NLRP3-deficient and wild-type mouse brains were further
stained for mouse IgG and isolectin B4. We could not detect mouse IgG in
the brain parenchyma.
product, formazan, in a dose-dependent manner (Figure 3C;
two-way ANOVA, p < 0.05; n = 4 per group). The amount
of formazan as shown with OD values is proportional
to the number of viable cells. In further experiments,
we detected no cleavage of caspase-3 in MCC950-treated
cells (Figure 3D), while MCC950 treatments significantly
decreased protein levels of both PCNA (Figures 3E,F;
one-way ANOVA, p < 0.05; n = 3 per group) and Ki-67
FIGURE 3 | NLRP3 inhibition attenuates cell proliferation in cultured
pericytes. (A) The cell lysates collected from cultured pericytes with different
passaging numbers were detected for NLRP3 with Western blot. (B)
Pericytes were treated with NLRP3 inhibitor, MCC950, at 0, 25, 50, and
100 nM for 24 h and then detected for cleaved caspase-1. After inhibition of
NLRP3, cleaved caspase-1 was nearly undetectable. (C) Cultured pericytes
were treated with MCC950 with various doses and analyzed for proliferation
with MTT assay every day for 7 days. Two-way ANOVA followed by Tukey
post hoc test, n = 4 per group. **p < 0.01 and ***p < 0.001. (D–H) Pericytes
were cultured and treated with MCC950 at indicated concentrations for 24 h.
Cell lysates were detected for cleaved caspase-3, PCNA, and Ki-67 with a
quantitative Western blot. As a positive control for cleavage of caspase-3, the
brain lysate from neuronal ATG5-deficient mice was used. The result in (D)
shows one experiment representative of four independent experiments. The
inhibition of NLRP3 reduces protein levels of PCNA and Ki-67 in a
dose-dependent manner. One-way ANOVA followed by Tukey post hoc test,
n = 3 per group for PCNA, and n = 4 per group for Ki-67. *p < 0.05 and
**p < 0.01. (I) cultured pericytes were further treated with recombinant IL-1β
at 0, 5, 10, and 50 ng/ml and analyzed with MTT assay every 2 days for
7 days. Two-way ANOVA analysis did not show the effects of IL-1β on cell
proliferation, n = 3 per group.
(Figures 3G,H; one-way ANOVA, p < 0.05; n = 4 per group),
which are two typical protein markers for cell proliferation.
Thus, inhibition of NLRP3 suppresses the proliferation
of pericytes.
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FIGURE 4 | NLRP3 inhibition attenuates protein expression of PDGFRβ and CD13 and inhibits phosphorylation of AKT and ERK in cultured pericytes. Pericytes
were cultured and treated with MCC950 at 0, 25, 50, and 100 nM for 24 h. (A,D,G) Western blot was used to detect PDGFRβ and CD13, as well as phosphorylated
and total protein levels of AKT, ERK, and NFκB p65. (B,C,E,F) Inhibition of NLRP3 reduces protein levels of PDGFRβ and CD13 and inhibits phosphorylation of AKT
and ERK with a dose-dependent pattern. one-way ANOVA followed by Tukey post hoc test, n = 4 per group. *p < 0.05, **p < 0.01 and ***p < 0.001.
(H) Phosphorylation of NFκB p65 is not significantly changed by inhibition of NLRP3. One-way ANOVA, n = 3 per group.
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FIGURE 5 | IL-1β increases protein expression of PDGFRβ and CD13 in cultured pericytes. Pericytes were cultured and treated with recombinant human IL-1β at 0,
5, 10, and 50 ng/ml for 24 h. (A,D) Western blot was used to detect PDGFRβ and CD13, as well as phosphorylated and total protein levels of AKT and ERK.
(B,C,E,F) Stimulation of IL-1β increases protein levels of PDGFRβ and CD13, and activates phosphorylation of AKT, but not ERK, in a dose-dependent manner.
One-way ANOVA followed by Tukey post hoc test, n = 3 per group. *p < 0.05 and **p < 0.01.
In additional experiments, we treated cultured pericytes with
recombinant IL-1β cytokine. IL-1β at 5, 10 and 50 ng/ml did
not alter the cell proliferation as measured with MTT assay
(Figure 3I; n = 3 per group).
NLRP3 Inhibition Attenuates the
Expression of PDGFRβ and CD13 in
Cultured Pericytes
PDGFRβ and CD13 are two protein markers of pericytes in the
brain, which mediate the physiological and pathophysiological
functions of pericytes (Lindahl et al., 1997; Rangel et al., 2007).
We observed that treatments with MCC950 inhibited expression
of PDGFRβ and CD13 in pericytes in a dose-dependent
manner (Figures 4A–C; one-way ANOVA, p < 0.05;
n = 4 per group). To analyze underlying mechanisms, through
which NLRP3 drives pericyte differentiation, we detected
phosphorylation of AKT, ERK, and NF-κB in MCC950-treated
cells. Activation of AKT and ERK is involved in pericyte
proliferation and migration (Bonacchi et al., 2001; Yao et al.,
2014). We observed that inhibition of NLRP3 reduced the
protein levels of both phosphorylated AKT and ERK in a
dose-dependent manner (Figures 4D–F; one-way ANOVA,
p < 0.05; n = 4 per group). However, phosphorylation of
NF-κB in pericytes was not significantly altered by treatments
with MCC950 (Figures 4G,H; one-way ANOVA, p = 0.094;
n = 3 per group).
IL-1β Increases the Expression of PDGFRβ
and CD13 in Cultured Pericytes
Although IL-1β did not increase pericyte proliferation
(Figure 3I), we hypothesized that IL-1β might affect the
differentiation of pericytes. We treated cultured pericytes
with IL-1β at different concentrations. IL-1β did increase
the protein expression of PDGFRβ and CD13 also with a
concentration-dependent pattern (Figures 5A–C; one-way
ANOVA, p < 0.05; n = 3 per group). As potential mechanisms
mediating effects of IL-1β activation, we observed that IL-1β
treatments significantly increased phosphorylation of AKT
but not of ERK (Figures 5D–F; one-way ANOVA, p < 0.05;
n = 3 per group).
Frontiers in Cellular Neuroscience | www.frontiersin.org 8 August 2020 | Volume 14 | Article 276
Quan et al. NLRP3 and Pericytes
FIGURE 6 | Inhibition of AKT signaling pathway suppresses protein
expression of PDGFRβ and CD13 and abolishes the effect of IL-1β in cultured
pericytes. Pericytes were cultured and treated with AKT inhibitor at 0, 0.5, 1,
and 5 µM for 24 h. (A–C) Western blot was used to detect phosphorylated
and total AKT, and GSK3β, which shows that phosphorylation of both AKT
and GSK3β was significantly inhibited by treatments with AKT inhibitors.
One-way ANOVA followed by Tukey post hoc test, n = 4 per group. (D–F)
The cell lysate from AKT inhibitor-treated pericytes were detected for protein
levels of PDGFRβ and CD13 with a quantitative Western blot. The inhibition of
AKT decreases protein levels of PDGFRβ and CD13 in a dose-dependent
manner. One-way ANOVA followed by Tukey post hoc test, n = 3 per group.
*p < 0.05, **p < 0.01 and ***p < 0.001. (G–I) Cultured pericytes were
pre-treated with 1 µM AKT inhibitor and then incubated with IL-1β at 0, 5, 10,
and 50 ng/ml, in the presence of AKT inhibitor for 24 h. AKT inhibition
abolished the effect of IL-1β on the up-regulation of PDGFRβ and
CD13 expression. one-way ANOVA followed by Tukey post hoc test,
n = 3 per group. **p < 0.01.
Inhibition of AKT Suppresses Expression
of PDGFRβ and CD13 in Cultured Pericytes
As activation of AKT in pericytes was suppressed by
NLRP3 inhibition but enhanced upon IL-1β activation,
we supposed that AKT signaling plays a key role in the
differentiation of pericytes. We treated pericytes with
AKT inhibitors at 0, 0.5, 1, and 5 µM. Phosphorylation
of AKT and phosphorylation of GSK3β, a kinase
down-stream to AKT, were both reduced (Figures 6A–C;
one-way ANOVA, p < 0.05; n = 4 per group), which
verified the successful inhibition of AKT signaling. With
such an inhibition, expression of both PDGFRβ and
CD13 was significantly down-regulated in a dose-dependent
manner (Figures 6D–F; one-way ANOVA, p < 0.05;
n = 3 per group).
In the following experiments, we treated cultured
pericytes with IL-1β at different concentrations in the
presence and absence of 1 µM AKT inhibitor. Without
co-treatment of AKT inhibitor, IL-1β activation did increase the
expression of PDGFRβ and CD13 in pericytes (Figures 6G–I;
one-way ANOVA, p < 0.05; n = 3 per group), which
corroborated our previous experiments (see Figure 5).
Interestingly, inhibition of AKT abolished the effect of IL-
1β on the up-regulation of PDGFRβ and CD13 proteins
in pericytes (Figures 6G–I; one-way ANOVA, p > 0.05;
n = 3 per group).
DISCUSSION
Pericytes play a central role in regulating microvascular
circulation and BBB function in the brain (Sweeney
et al., 2016). Our study demonstrated that the deletion
of NLRP3 under physiological conditions decreases the
coverage of pericytes and protein levels of PDGFRβ and
CD13 in cerebral blood vessels. PDGFRβ and CD13, together
with neural/glial antigen-2 and CD146 are expressed in
capillary-associated pericytes, and often used as protein
markers of brain pericytes (Smyth et al., 2018). PDGFRβ and
CD13 also trigger proliferation and migration of pericytes
after stimulation with angiogenesis-associated growth factors
(Lindahl et al., 1997; Rangel et al., 2007). Thus, the reduction
of CD13 and PDGFRβ represents not only the loss of
pericytes but also the dysfunction of pericytes in the brain.
Indeed, we observed that the deletion of NLRP3 reduces
the vasculature in the brain, which corroborates a recent
observation that the dysfunction of pericytes decreases
the length of cerebral blood vessels in PDGFRβ-mutated
mouse brain (Montagne et al., 2018). Our study suggests
that NLRP3 is essential in the maintenance of functional
pericytes in healthy brains. We did not observe the leakage of
IgG from serum into brain parenchyma in NLRP3-deficient
mice. However, we could not exclude the impairment in the
ultrastructure of BBB, which might be caused by the lack
of NLRP3.
NLRP3-contained inflammasome activates caspase-1 and
produces active IL-1β (Gross et al., 2011). MyD88 mediates
inflammatory activation after the challenges of TLRs ligands
and IL-1β (O’Neill and Bowie, 2007). We observed that
deficiency of either NLRP3 or MyD88 decreases protein
levels of PDGFRβ and CD13 in the mouse brain. We
supposed that NLRP3 drives a basal inflammatory activation
in pericytes and promotes pericyte survival, although it was
difficult to detect the secretion of IL-1β from pericytes
in the brain. In cultured pericytes, we did observe that
caspase-1 is activated and inhibition of NLRP3 attenuates
Frontiers in Cellular Neuroscience | www.frontiersin.org 9 August 2020 | Volume 14 | Article 276
Quan et al. NLRP3 and Pericytes
phosphorylation of multiple inflammation-related kinases, such
as AKT and ERK, and perhaps also NFκB (p = 0.094),
which is correlated with decreased cell proliferation and
PDGFRβ and CD13 expression. Moreover, treatments with
IL-1β increase PDGFRβ and CD13 expression in our cultured
pericytes. It is consistent with a report that TNF-α at
10 ng/ml promotes cultured pericytes to proliferate and
migrate (Tigges et al., 2013). Thus, it is not surprising
that angiogenesis is activated with pericyte proliferation in
inflammatory lesion sites of multiple sclerosis (Girolamo
et al., 2014). However, we observed that IL-1β treatments
did not increase pericyte proliferation, which suggests that
the regulation of pericyte proliferation by NLRP3 might not
depend on IL-1β production. During early wound healing,
NLRP3 facilitates angiogenesis; and the production of IL-
1β was not always necessary for this repair process, either
(Weinheimer-Haus et al., 2015).
As there are no pericyte-specific NLRP3-knockout mice
available, we had to work on animals with an overall deficiency of
NLRP3. We know that NLRP3 is expressed also in non-pericyte
brain cells, i.e., microglia (Heneka et al., 2013). We cannot
exclude the possibility that NLRP3 deficiency in microglia
decreases the coverage of pericytes in brain vessels. Microglia,
located at the perivascular space, is the major component of
the neurovascular unit. In response to systemic inflammation,
microglia protect BBB integrity in an initial phase by expressing
tight-junction protein Claudin-5 and turn to damage BBB
through phagocytizing astrocytic end-feet after the inflammation
is sustained (Haruwaka et al., 2019). However, the regulation of
BBB function and especially pericyte activation by blood vessel-
associated microglia under physiological conditions has not been
fully explored.
It should be noted that NLRP3 might not fully offer
protective effects on pericytes when the inflammatory
activation surrounding pericytes is uncontrolled. In the
AD brain, NLRP3-contained inflammasome is activated
(Heneka et al., 2013), whereas, pericytes are impaired
and lost (Sengillo et al., 2013; Nation et al., 2019). There
must be other mechanisms, which damage pericytes,
compensating for the protective effects of NLRP3 activation.
For example, brain-delivered neurotrophic factor (BDNF)
drops down and the activation of the BDNF receptor,
TrkB, is impaired in the AD brain (Tanila, 2017). TrkB
signaling regulates pericyte migration. The deletion of TrkB
in pericytes reduces pericyte density and causes abnormal
vasculogenesis in the heart (Anastasia et al., 2014). The
deletion of NLRP3 in APP or Tau-transgenic mice was
reported to rescue neuronal functions and shift microglial
activation from pro-inflammatory to anti-inflammatory profile
(Heneka et al., 2013; Ising et al., 2019). Unfortunately, the
microvascular circulation in NLRP3-deficient AD mice has not
been investigated.
AKT is a known kinase to regulate cell survival,
proliferation, and angiogenesis in response to extracellular
signals (Manning and Cantley, 2007). AKT activation
prevents pericyte loss in diabetic retinopathy (Yun et al.,
2018). In our experiments, AKT phosphorylation is reduced
by NLRP3 inhibition but enhanced by IL-1β activation.
Inhibition of AKT directly down-regulates the expression
of PDGFRβ and CD13 and also abolishes the effect
of IL-1β to elevate the protein levels of PDGFRβ and
CD13 in pericytes. Thus, AKT activation might mediate
the protective effects of NLRP3 in pericytes. As PDGFRβ
activation induces phosphorylation of AKT (Lehti et al.,
2005), PDGFRβ and AKT even activate each other and
form positive feedback to maintain the healthy pericytes in
the brain.
In summary, our study suggested that NLRP3 activation
maintains healthy pericytes in the brain through activating
AKT signaling pathway. In the following studies, we are
evaluating potential cerebral vascular impairment in AD mice
with both genetic and pharmacological inhibitions of NLRP3.
The potential adverse effects of NLRP3 inhibition on pericyte
function and microcirculation should be considered when
NLRP3 inhibitors are administered to treat AD or other
inflammatory disorders.
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